Nephros Has New Director of Sales

Nephros Inc.— a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification—has hired Shane Sullivan as director of U.S. sales.

Sullivan has spent nearly two decades in a sales leadership role in the healthcare, life science and biopharmaceutical industry. Prior to joining Nephros, he led the sales team at Saxton Bradley with a focus on the healthcare and scientific markets. Before Saxton Bradley, Sullivan was the Western regional sales manager at Thermo Scientific. While there, he led the $175 million laboratory furnishings and airflow products division to ten consecutive double-digit increases in the region. His extensive work within the architectural design, engineering and contracting communities significantly contributed to their sales on a national level. Prior to Thermo, Mr. Sullivan worked at Applied Instruments, where he represented a variety of equipment manufacturers focused on solutions for the healthcare, life science and bio pharmaceutical research markets. At Applied Instruments, he helped grow their business, establish stronger roots for their organization in the region and developed a strong understanding of the distribution market. Prior, at MDT Castle, he led the launch and direct sales efforts of their life science and pharmaceutical sterilization business. His sales efforts ultimately contributed to the merger that formed Getinge-Castle. Mr. Sullivan earned his undergraduate degree in business administration from the University of Southern California.

“The Nephros line of ultrafiltration products represents a significant asset for infection control and the production of ultrapure water,” said Sullivan of his new company. “I am excited to be joining the Nephros team and look forward to ramping up market adoption of the company’s products.”

Nephros recently introduced product line extensions for the hospital infection control market which include a more durable filter design to withstand the higher pressures of hospital plumbing, filter covers to improve the aesthetics of the filters in hospital showers, and the SafeSpout as a convenient endpoint filter to address acute outbreak scenarios. In a study involving two major U.S. hospitals, the Nephros DSU system was shown to be effective in reducing waterborne Legionella bacteria to undetectable levels, an effect which was sustained for the three-month study period.

Nephros has an ongoing collaboration agreement with Steris Corp. related to its ultrafiltration technology.

The Nephros hemodiafiltration (HDF) system is designed to improve the quality of life for end-stage renal sisease (ESRD) patients while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as “middle molecules.” These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

Nephros is headquartered in River Edge, N.J.